Drugs / CMAB819
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04659369 | Sep 2020 → Oct 2023 | head and neck squamous cell carcinoma | Taizhou Mabtech Pharmaceutical Co.,Ltd | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CMAB819 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04659369 ↗ |
| Route | Intravenous | “CMAB819 480 mg intravenous (IV) solution for Injection every 4 weeks” NCT04659369 ↗ |